Patients with Type 2 diabetes have been shown to have an increased risk for developing cancer, especially obesity related cancers. There is some evidence that within the class of sulfonylureas there is a difference in cancer risk; gliclazide could…
ID
Bron
Verkorte titel
Aandoening
Type 2 diabetes, cancer, kanker.
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Within-sulfonylurea-class differences in obesity-related cancer risk (hazard ratio).
Doel van het onderzoek
Patients with Type 2 diabetes have been shown to have an increased risk for developing cancer, especially obesity related cancers. There is some evidence that within the class of sulfonylureas there is a difference in cancer risk; gliclazide could be associated with a decreased cancer risk when compared to the other sulfonylureas.
Onderzoeksopzet
Hazard ratio will be calculated for a period up to 10 years.
Onderzoeksproduct en/of interventie
Individual sulfonylurea treatment (gliclazide, glimepiride, tolbutamide, glibenclamide)
Algemeen / deelnemers
Dennis Schrijnders
Zwolle 8025 BT
The Netherlands
0031-38-4247763
d.schrijnders@isala.nl
Wetenschappers
Dennis Schrijnders
Zwolle 8025 BT
The Netherlands
0031-38-4247763
d.schrijnders@isala.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Type 2 diabetes patients treated with sulfonylureas
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Type 2 diabtes patientes treated with long-acting or mixed insulin before oral glucose lowering agents and those receiving insulin on top of sulfonylurea at study entry.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL6035 |
| NTR-old | NTR6166 |
| Ander register | : ZODIAC-55, METC 13.0765 |